AbbVie Inc. (NYSE:ABBV) Holdings Lifted by Oxler Private Wealth LLC

Oxler Private Wealth LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 0.8% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 16,855 shares of the company’s stock after buying an additional 140 shares during the period. AbbVie accounts for 1.2% of Oxler Private Wealth LLC’s investment portfolio, making the stock its 23rd largest position. Oxler Private Wealth LLC’s holdings in AbbVie were worth $3,531,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also bought and sold shares of the company. Baldwin Investment Management LLC lifted its holdings in shares of AbbVie by 1.4% during the first quarter. Baldwin Investment Management LLC now owns 27,905 shares of the company’s stock valued at $5,847,000 after purchasing an additional 372 shares during the last quarter. Norden Group LLC lifted its holdings in shares of AbbVie by 24.7% during the first quarter. Norden Group LLC now owns 22,041 shares of the company’s stock valued at $4,618,000 after purchasing an additional 4,360 shares during the last quarter. Werba Rubin Papier Wealth Management lifted its holdings in shares of AbbVie by 7.7% during the first quarter. Werba Rubin Papier Wealth Management now owns 2,092 shares of the company’s stock valued at $438,000 after purchasing an additional 149 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in shares of AbbVie by 2.6% during the first quarter. Mackenzie Financial Corp now owns 2,499,736 shares of the company’s stock valued at $523,745,000 after purchasing an additional 62,437 shares during the last quarter. Finally, Facet Wealth Inc. lifted its holdings in shares of AbbVie by 3.5% during the first quarter. Facet Wealth Inc. now owns 2,481 shares of the company’s stock valued at $486,000 after purchasing an additional 83 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of NYSE ABBV opened at $190.22 on Monday. AbbVie Inc. has a twelve month low of $163.81 and a twelve month high of $218.66. The stock’s 50 day moving average price is $187.62 and its 200-day moving average price is $189.85. The company has a market capitalization of $336.00 billion, a PE ratio of 80.94, a PEG ratio of 1.25 and a beta of 0.48. The company has a quick ratio of 0.64, a current ratio of 0.76 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.40 by $0.06. AbbVie had a net margin of 7.31% and a return on equity of 412.03%. The business had revenue of $13.34 billion during the quarter, compared to analyst estimates of $12.91 billion. During the same period in the prior year, the business posted $2.31 earnings per share. The company’s revenue was up 8.4% on a year-over-year basis. On average, equities analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be issued a $1.64 dividend. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.45%. AbbVie’s dividend payout ratio (DPR) is presently 279.15%.

Wall Street Analyst Weigh In

ABBV has been the topic of a number of recent analyst reports. Cantor Fitzgerald initiated coverage on AbbVie in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $210.00 price objective on the stock. Guggenheim raised their price objective on AbbVie from $214.00 to $216.00 and gave the company a “buy” rating in a research note on Tuesday, April 29th. Bank of America raised their price objective on AbbVie to $204.00 and gave the company a “hold” rating in a research note on Monday, June 9th. BNP Paribas raised AbbVie to a “hold” rating in a research note on Thursday, May 8th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $194.00 price objective on shares of AbbVie in a research note on Tuesday, April 8th. Eight investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $211.29.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.